Organisation paid for research Program year 2022 Source: CMS Open Payments

PMG Research LLC

Neither a doctor nor a teaching hospital

Research payments

$1,280,587

161 payments

Through program year 2022, PMG Research LLC is reported as receiving $1,280,587 in research payments, across 161 payments.

By program year

4 rows

Year	Kind	Amount	Payments
2022	Research	$1,909	2
2021	Research	$581,017	29
2020	Research	$99,593	48
2019	Research	$598,068	82

Breakdown

Who paid Research payments · program years 2019–2022

GlaxoSmithKline, LLC. $612,000 49 payments
Ironwood Pharmaceuticals, Inc $523,477 55 payments
Shire North American Group Inc $60,890 26 payments
Takeda Pharmaceuticals U.S.A., Inc. $50,152 16 payments
SK Life Science, Inc. $20,366 14 payments
Celgene Corporation $13,701 1 payment

Studies the money was for Research payments · program years 2019–2022

Study name not reported $533,939 16 payments
C3718-302 $300,629 7 payments
McP-103-312 $182,186 21 payments
A Phase III, Randomized, Multicenter, Parallel-Group, Double-Blind, DO $46,464 20 payments
Study of the Effect of Shp647 As Maintenance Treatment in Participants With Moderate to Severe Ulcerative Colitis Who Achieved Clinical Response in Induction Studies $36,366 10 payments
A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Efficacy and Safety Study of Shp647 As Induction Therapy in Subjects With Moderate to Severe Ulcerative Colitis Figaro UC 302 $25,538 10 payments
MD-7246_Mcp103-205 $22,357 10 payments
McP-103-205 $18,306 17 payments
A Multi-Center, Randomized, Double-Blind, Parallel-Group, Placebo-Cont $16,206 10 payments
A Phase 3 Randomized, Open-Label (Sponsor-Blind), Active-Controlled, P $15,391 3 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.